Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023383 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4P2RY14ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1072684 | 0.99 | CHRNB2 (0.47) | CHRNB2CHRNA4P2RY14ESR1ESR2 | |
| SCHEMBL1023489 | 0.85 | CHRNB2 (0.54) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1022339 | 0.81 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL1022337 | 0.81 | CHRNB2 (0.52) | CHRNB2CHRNA4P2RY14 | |
| Cadaverine Tartrate SCHEMBL1023809 | 0.77 | P2RY14 (0.45) | CHRNB2CHRNA4P2RY14 | |
| SCHEMBL2413769 | 0.76 | CHRNB2 (0.41) | CHRNB2CHRNA4P2RY14ESR1ESR2 | |
| SCHEMBL2413772 | 0.76 | CHRNB2 (0.41) | CHRNB2CHRNA4P2RY14ESR1ESR2 | |
| SCHEMBL7455117 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNA4P2RY14 | |
| Cadaverine Tartrate SCHEMBL1023378 | 0.74 | CHRNB2 (0.43) | CHRNB2CHRNA4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | claimed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| EP-2272847-A1 | Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors | NeuroSearch A/S (DK) | 2011-01-12 | — | — | EP | disclosed |
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1869033-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108789-A1 | NOVEL ENANTIOMERS AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137625-A1 | Novel Enantiomers and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | CHRNB2 90/4885CHRNA4 129/4885P2RY14 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.